Evolution of Nevi During Treatment With Natalizumab | Zendy

E. Castela | Zendy; Christine LebrunFrénay | Zendy; M. Laffon | Zendy; Fanny Rocher | Zendy; Mikaël Cohen | Zendy; Nathalie CardotLeccia | Zendy; Philippe Bahadoran | Zendy; J.P. Lacour | Zendy; Jean-Paul Ortonne | Zendy; Thierry Passeron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evolution of Nevi During Treatment With Natalizumab

Author(s) -

E. Castela,

Christine LebrunFrénay,

M. Laffon,

Fanny Rocher,

Mikaël Cohen,

Nathalie CardotLeccia,

Philippe Bahadoran,

J.P. Lacour,

Jean-Paul Ortonne,

Thierry Passeron

Publication year - 2010

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archdermatol.2010.243

Subject(s) - medicine , natalizumab , dermatology , melanoma , multiple sclerosis , prospective cohort study , cohort , nevus , malignant transformation , pathology , immunology , cancer research

Natalizumab is a monoclonal antibody directed against α₄ integrin used in the treatment of multiple sclerosis (MS). Four cases of melanomas occurring in patients prescribed natalizumab to treat MS were recently reported. Although some fundamental data suggested that α₄β1 integrin could be linked to the invasiveness of melanoma, none showed any relation with the transformation of melanocytes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research